Who: VectivBio Holding AG and Comet Therapeutics Inc.
What: On 31 August, Basel, Switzerland-based VectivBio said it would acquire Cambridge, MA-based Comet, a company focused on developing small molecule drugs for inherited metabolic
Deal Snapshot: VectivBio is expanding its existing focus on rare diseases into inherited metabolic disorders, which affect about one in 800 live births and cause significant mortality in infants and young people.
Who: VectivBio Holding AG and Comet Therapeutics Inc.
What: On 31 August, Basel, Switzerland-based VectivBio said it would acquire Cambridge, MA-based Comet, a company focused on developing small molecule drugs for inherited metabolic